NOTE: STOCKS IN THIS WATCHLIST ARE NOT GEARED TOWARDS ANY SPECIFIC TYPE OF TRADING (DAY, SWING, LONG). HOWEVER, THEY ARE EITHER TRENDING TOWARDS A BULLISH TECHNICAL CHART OR CURRENTLY IN ONE. ANY TECHNICAL ANALYSIS IS PROVIDED IN THE CHART. PLEASE DO YOUR OWN DUE DILIGENCE BEFORE CONSIDERING INVESTING IN THESE STOCKS. (The Shares Float is based on figures from FinViz.Com).
Stocks highlighted in this watchlist include: $CXRX, $NSPR, $PTIE
CXRX: Float of 45.5 million shares with 6.3% short. This is a technical play only.
NSPR: Float of 7.33 million shares with 6.57% short.
InspireMD, a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that the New York Stock Exchange has accepted the Company's plan to regain compliance with the NYSE American's stockholder's equity continued listing standard (Part 10, Section 1003(a)(iii)). As previously disclosed, the NYSE American notified the Company on August 17, 2017, that it had fallen below the NYSE's continued listing standards.
Based on a review of the compliance plan and information submitted by the Company, the Exchange determined that the Company made a reasonable demonstration of its ability to make substantial progress toward regaining compliance with Section 1003(a)(iii) of the Company Guide by February 17, 2018.
Postpones Special Meeting of Stockholders to October 27, 2017. My only issue is that it may involve a reverse stock split.
PTIE: Float of 5.15 million shares with 13.33% short. Pain Therapeutics Inc, operates in the healthcare industry, which continues to endure a more demanding healthcare agenda, and the global need for innovative, cost-effective medicines continues to rise. Healthcare analysts are forecasting for the entire industry, a positive double-digit growth of 18.68% in the upcoming year, and an enormous growth of 53.80% over the next couple of years.
On Tuesday, the Company announced A Phase 1 clinical trial of PTIE’s new investigational drug, PTI-125, showed that it was safe and well-tolerated in healthy volunteers, paving the way for a Phase 2 trial in adults with Alzheimer’s Disease.